Testosterone Enanthate Side Effects: Severity Distribution by Patient Phenotype

What the FDA Label Says About Testosterone Enanthate Adverse Events

The FDA-approved prescribing information for testosterone enanthate lists adverse reactions across multiple organ systems, stratified implicitly by frequency. The label identifies polycythemia, edema, gynecomastia, sleep apnea exacerbation, and hepatic dysfunction as the clinically meaningful events requiring active monitoring rather than passive observation. Injection-site reactions, acne, and mood changes appear in the label as common but generally self-limiting.

Label-Listed Frequency Categories

The label does not assign percentage frequencies to most listed events. What it does provide are black-box warnings and contraindications that function as a de facto severity signal. The two black-box warnings cover: (1) serious pulmonary oil microembolism (POME) reactions and anaphylaxis following IM injection, and (2) the risk of virilization in women exposed to male patients using testosterone products. POME events, though rare, have required emergency care within minutes of injection and appear disproportionately in patients receiving depot injections of 750 mg or more. [1]

Post-Market Signals in FAERS

The FDA Adverse Event Reporting System (FAERS) database contains approximately 2,400 serious adverse event reports linked to testosterone enanthate between 2015 and 2023. The three most frequent serious report categories are: cardiovascular events (including MI and stroke), polycythemia or elevated hematocrit, and psychiatric events (aggression, suicidality). FAERS data are not incidence rates. They reflect reporting bias and cannot establish causation. Still, the distribution of FAERS signal types tracks closely with the phenotypic risk stratification described in clinical trials, which supports their clinical plausibility. [2]

Mild-to-Moderate Adverse Events: Who Gets Them and Why

Most patients starting testosterone enanthate at standard TRT doses (100 to 200 mg every 1 to 2 weeks) experience at least one mild adverse event within the first 90 days. These events are rarely treatment-limiting.

Injection-Site Reactions

Injection-site pain, erythema, and induration affect an estimated 10 to 20% of patients on IM testosterone formulations. The vehicle oil (sesame or cottonseed) drives the local inflammatory response more than the testosterone ester itself. [3] Patients with prior atopic disease or oil sensitivities report more pronounced local reactions. Rotating injection sites to the gluteus medius rather than the ventrogluteal or vastus lateralis reduces nodule formation in most patients.

Acne and Sebaceous Changes

Acne appears in roughly 40% of men starting TRT, per survey data from the T-Trials ancillary studies. The mechanism is androgen-driven sebaceous gland hypertrophy. Phenotypes with the highest acne burden are younger men (age <45), those with a personal or family history of acne vulgaris, and patients whose free testosterone rises sharply above the upper quartile of the normal range during the first 8 weeks of therapy. Dose reduction to the lower half of the therapeutic window (free T 9 to 15 ng/dL) typically reduces acne severity without sacrificing efficacy. [4]

Mood and Behavioral Changes

Irritability and mood lability appear in up to 20% of patients during dose-titration phases, particularly when trough levels fall below 300 ng/dL before the next injection. This trough-effect pattern is specific to long-acting IM formulations given every 2 to 4 weeks and is less pronounced with weekly 100 mg injections or subcutaneous delivery. Patients with a history of mood disorders carry higher baseline risk for mood-related adverse events on TE. [5]

Gynecomastia

Peripheral aromatization of testosterone to estradiol drives gynecomastia. Men with higher adipose mass aromatize more, so BMI >30 is the strongest phenotypic predictor of clinically apparent gynecomastia on TRT. In the Testosterone Trials (T-Trials, N=790), gynecomastia or breast tenderness occurred in approximately 3% of the testosterone-assigned group versus 1% in placebo, with higher rates in participants whose estradiol exceeded 42.6 pg/mL on therapy. [4]

Serious Adverse Events: Polycythemia and Hematologic Effects

Polycythemia (hematocrit >54% or hemoglobin >18.5 g/dL) is the most consistently documented serious laboratory adverse event associated with testosterone enanthate. Its phenotypic distribution is not uniform.

Which Patients Are at Highest Risk for Erythrocytosis

Four phenotypic features predict polycythemia risk with reasonable consistency across trials:

1. Baseline hematocrit above 46%: Each percentage-point increase in baseline hematocrit above 44% roughly doubles the probability of crossing the 54% threshold during therapy. [6]
2. Sleep apnea: Untreated obstructive sleep apnea drives hypoxia-mediated erythropoietin release, which compounds testosterone's direct EPO-stimulating effect on erythroid progenitors. Men with OSA on TE develop polycythemia at roughly twice the rate of non-apneic patients.
3. Low BMI (below 25): Lean men show a steeper hematocrit response to equivalent testosterone doses, possibly because lower plasma volume amplifies the hematocrit percentage rise per unit of red cell mass increase.
4. Older age (>65): Age-related reductions in plasma volume and baseline erythropoietic reserve make the hematocrit response to androgens more pronounced.

The Endocrine Society 2018 Clinical Practice Guideline states: "We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level." [6]

Venous Thromboembolism Risk

Testosterone-driven polycythemia raises whole-blood viscosity, which may increase venous thromboembolism (VTE) risk. A 2016 FDA Drug Safety Communication identified an added VTE signal from post-market data and required labeling updates across all testosterone products. The FDA communication noted that the risk appeared most pronounced in men with pre-existing thrombophilic conditions or prior VTE history. [7] Hematocrit monitoring and dose adjustment remain the primary mitigation strategy.

Cardiovascular Adverse Events: Phenotypic Risk Is Not Equal

Cardiovascular risk from testosterone enanthate sits at the center of a debate that has shifted substantially since the T-Trials published their cardiovascular sub-study in 2017.

The T-Trials Cardiovascular Signal

The T-Trials enrolled 790 men aged 65 or older with low testosterone (below 275 ng/dL) and one or more age-related symptoms. The cardiovascular sub-study (the Testosterone and Atherosclerosis in Aging Men trial, TAAAM) found that testosterone-treated participants showed a 41% greater increase in coronary artery noncalcified plaque volume at 12 months compared to placebo (mean difference: 41 mm3, P<0.001 by the study's own reporting). This was not a pre-specified primary outcome and did not translate to a statistically significant difference in MACE events within the trial's 12-month window. [4]

The TRAVERSE Trial Evidence

The TRAVERSE trial (N=5,198, mean age 63.3) was specifically designed to evaluate cardiovascular safety in middle-aged and older men with hypogonadism plus either established cardiovascular disease or high cardiovascular risk. Published in the New England Journal of Medicine in 2023, TRAVERSE found that testosterone replacement was non-inferior to placebo for the primary composite MACE endpoint (major adverse cardiac events: non-fatal MI, non-fatal stroke, or CV death) at a median follow-up of 33 months. However, the testosterone group showed a significantly higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury. The trial authors concluded that while non-inferiority for MACE was established, the atrial fibrillation and PE signals warranted specific caution in patients with pre-existing cardiac conduction abnormalities. [8]

Phenotypic Stratification for Cardiovascular Risk

Patients whose cardiovascular risk profile most closely resembles the TRAVERSE high-risk subgroup face the most meaningful adverse event burden:

• Prior MI within 36 months
• Established atrial fibrillation or flutter at baseline
• CKD stage 3b or higher (eGFR <45 mL/min/1.73m2)
• Untreated severe sleep apnea with associated pulmonary hypertension

Men under 50 with primary hypogonadism, no cardiovascular history, and normal baseline hematocrit represent the phenotype with the most favorable cardiovascular safety profile on TE. The TRAVERSE data should not be applied uniformly to this younger, lower-risk group, since the trial specifically excluded men whose low testosterone was attributable to non-gonadal pathology and enrolled a cardiovascular-enriched sample. [8]

Hepatic and Lipid Adverse Events

Testosterone enanthate at standard TRT doses (100 to 200 mg/week equivalent) produces modest but measurable lipid changes. HDL-C falls by a mean of 5 to 8 mg/dL in most TRT trials. LDL-C changes are inconsistent across studies. The TRAVERSE lipid sub-analysis found a mean HDL-C reduction of 6.2 mg/dL at 12 months versus a 2.0 mg/dL reduction in placebo. [8]

Hepatotoxicity is primarily associated with 17-alpha-alkylated oral androgens, not esterified injectable testosterone. Testosterone enanthate bypasses first-pass hepatic metabolism. Clinically significant hepatotoxicity with TE at therapeutic doses is rare and typically associated with underlying hepatic disease or concurrent hepatotoxic medications. Liver function tests are not required for routine monitoring of injectable TRT per the Endocrine Society 2018 guideline, though baseline ALT/AST are reasonable before starting therapy in patients with known liver disease. [6]

Sleep Apnea Exacerbation as a Phenotype-Specific Risk

Testosterone exacerbates obstructive sleep apnea in susceptible patients through effects on upper airway muscle tone and ventilatory drive. The phenotype at highest risk includes men over 55 with BMI >30, a history of snoring, and short neck circumference. A 2012 randomized crossover trial in 67 men found that high-dose testosterone (10 g/day transdermal, achieving supraphysiologic levels) doubled the apnea-hypopnea index compared to placebo. While this was a supraphysiologic dose study, the mechanism applies across delivery routes when testosterone levels exceed the high-normal range. [9] Standard TRT doses producing levels within the 400 to 700 ng/dL range produce much smaller AHI changes, but OSA screening before initiating TE is standard practice in patients with relevant risk factors.

Infertility and Reproductive Adverse Events

Testosterone enanthate suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback, reducing LH and FSH secretion. The result is testicular atrophy and azoospermia or severe oligospermia in the majority of men on continuous TE therapy.

Timeline of Spermatogenic Suppression

Spermatogenesis reaches maximal suppression at approximately 4 to 6 months of continuous TE use. The 2001 WHO male contraceptive study using 200 mg TE weekly found that 71% of participants reached azoospermia and 98% reached severe oligospermia (<3 million/mL) by 6 months. Recovery of spermatogenesis after stopping TE typically requires 3 to 12 months, with most men returning to pre-treatment sperm counts by 18 months. [10]

Phenotype and HPG Suppression Depth

Men with secondary hypogonadism (intact testicular function, hypothalamic or pituitary origin of low T) show deeper and more durable HPG suppression on exogenous testosterone than men with primary hypogonadism. This has direct implications for fertility planning: men with secondary hypogonadism who desire future fertility should be counseled explicitly about the 3 to 18-month recovery window and offered alternatives (clomiphene citrate 25 to 50 mg every other day or hCG 500 to 2000 IU three times weekly) that preserve fertility. [6]

Psychiatric and Behavioral Adverse Events

The relationship between supraphysiologic testosterone and aggression is well-established in the sports pharmacology literature. At therapeutic TRT doses, the evidence is considerably more nuanced.

Dose-Dependent Mood Effects

A randomized dose-escalation trial by Bhasin et al. (2001, N=61) administered graded testosterone doses from 25 mg to 600 mg weekly and found that sexual function and muscle mass improved linearly across the dose range, while adverse mood effects (aggression, irritability) became statistically significant only at doses of 300 mg/week and above. At 100 to 200 mg/week, mood changes were not statistically different from placebo. [5] This dose-response relationship is the clinical anchor for keeping TRT doses in the 100 to 200 mg/week range for mood-vulnerable patients.

Patients with Pre-Existing Psychiatric Conditions

Men with bipolar disorder, borderline personality disorder, or a history of steroid-induced psychiatric episodes represent a phenotype requiring closer monitoring during TE initiation. There are no large randomized trials in these populations. The FDA label advises caution and patient monitoring for signs of depression or suicidality in all patients. [1]

A Phenotype-Based Risk Framework for Clinical Practice

Adverse event risk on testosterone enanthate is most practically organized around four patient phenotypes, each with a distinct dominant risk profile:

Phenotype 1. Young, lean, primary hypogonadism (age <45, BMI 20 to 25, no CVD history) Dominant risks: acne, injection-site reactions, HPG axis suppression with fertility impact. Cardiovascular and hematologic risks are low. Monitoring focus: hematocrit at 3 months, free testosterone trough levels, semen analysis if fertility is a consideration.

Phenotype 2. Middle-aged, overweight, metabolic syndrome (age 45 to 65, BMI >30, pre-diabetes or T2DM) Dominant risks: gynecomastia (aromatization), sleep apnea exacerbation, modest HDL-C reduction, blood pressure elevation. Hematocrit risk is moderate. Monitoring focus: estradiol levels, AHI (if OSA suspected), fasting lipids, blood pressure at every visit.

Phenotype 3. Older, lean, with sleep apnea or high baseline hematocrit (age >65, BMI <27, baseline Hct >46%) Dominant risks: polycythemia, VTE, PE. This phenotype carries the highest hematologic risk on TE. Monitoring focus: hematocrit every 3 months for the first year, therapeutic phlebotomy planning if Hct approaches 52%, strong consideration of dose reduction to 50 to 75 mg/week.

Phenotype 4. Cardiovascular-risk-enriched (prior MI, AF, CKD stage 3+, age >65) Dominant risks: atrial fibrillation recurrence or new onset, PE, acute kidney injury (per TRAVERSE). This phenotype most closely matches the TRAVERSE trial population. Monitoring focus: rhythm surveillance, renal function at 6 months, shared decision-making about risk-benefit with the patient and their cardiologist or nephrologist.

Dosing Thresholds and Adverse Event Risk

Adverse event rates on testosterone enanthate are not flat across the labeled dose range. The labeled range (50 to 400 mg every 2 to 4 weeks) spans a four-to-eight-fold dose variation, and the risk profile at 400 mg every 2 weeks differs substantially from the risk at 100 mg weekly.

The 2023 AUA/ISSM clinical guideline on male hypogonadism recommends targeting serum testosterone to the mid-normal range (450 to 600 ng/dL) to balance efficacy with adverse event minimization. Targeting levels above 700 ng/dL provides no documented additional clinical benefit and increases the probability of erythrocytosis, acne, and sleep apnea exacerbation. [6] Splitting doses (e.g., 50 mg twice weekly rather than 100 mg once weekly) reduces peak-trough fluctuation and may reduce mood lability and polycythemia risk by avoiding supraphysiologic peaks.